Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

European marketing application submitted for RenaGel

July 10, 1998

Ditropan XL shows favorable efficacy/side effect profile in phase III study

July 8, 1998

Blockade of angiotensin II receptor reduces radiation-induced renal and lung injury

July 7, 1998

P&U characterizes dual inhibitor of both 5alpha-reductase isozymes

July 3, 1998

Positive preliminary results reported for extended-use clinical trial of RenaGel

July 3, 1998

Nippon Shinyaku discovers new treatment for urinary incontinence

June 12, 1998

ET antagonist protects against ciclosporin-induced nephrotoxicity in rats

June 11, 1998

New and established treatments for BPH reviewed at AUA

June 10, 1998

Urinary reflux product enters phase III

June 9, 1998

Dornier's BPH device approved by FDA

June 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...